{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:10:02Z","timestamp":1742962202156,"version":"3.40.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Huashan Hospital, Fudan University","award":["HSBY2021007"],"award-info":[{"award-number":["HSBY2021007"]}]},{"name":"Shanghai Shenkang Clinical Innovation Project","award":["SHDC12020112"],"award-info":[{"award-number":["SHDC12020112"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94477-1","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T09:06:17Z","timestamp":1742720777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiepileptic drugs failed to prevent initial seizures or improve survival outcomes in patients with primary CNS lymphoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0565-0117","authenticated-orcid":false,"given":"Mengxue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"issue":"3","key":"94477_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.14073","volume":"174","author":"MS Shiels","year":"2016","unstructured":"Shiels, M. S. et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br. J. Haematol. 174(3), 417\u2013424 (2016).","journal-title":"Br. J. Haematol."},{"issue":"5","key":"94477_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10552-019-01144-8","volume":"30","author":"D Dandachi","year":"2019","unstructured":"Dandachi, D. et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control. 30(5), 477\u2013488 (2019).","journal-title":"Cancer Causes Control."},{"issue":"5","key":"94477_CR3","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri, A. J. et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 3(5), e217\u2013e227 (2016).","journal-title":"Lancet Haematol."},{"issue":"32","key":"94477_CR4","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier, C. et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study. J. Clin. Oncol. 40(32), 3692\u20133698 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"94477_CR5","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri, A. J. M. et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 4(11), e510\u2013e523 (2017).","journal-title":"Lancet Haematol."},{"issue":"7","key":"94477_CR6","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"S Jarius","year":"2023","unstructured":"Jarius, S. et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J. Neurol. 270(7), 3341\u20133368 (2023).","journal-title":"J. Neurol."},{"issue":"1","key":"94477_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","volume":"9","author":"AJM Ferreri","year":"2023","unstructured":"Ferreri, A. J. M. et al. Primary central nervous system lymphoma. Nat. Rev. Dis. Primers. 9(1), 29 (2023) (Published 2023 Jun 15).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"3","key":"94477_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/epi.17171","volume":"63","author":"J Royer","year":"2022","unstructured":"Royer, J. et al. Epilepsy and brain network hubs. Epilepsia. 63(3), 537\u2013550 (2022).","journal-title":"Epilepsia."},{"issue":"1","key":"94477_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","volume":"139","author":"DY Chen","year":"2018","unstructured":"Chen, D. Y., Chen, C. C., Crawford, J. R. & Wang, S. G. Tumor-related epilepsy: epidemiology, pathogenesis and management. J. Neurooncol. 139(1), 13\u201321 (2018).","journal-title":"J. Neurooncol."},{"issue":"9","key":"94477_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1684\/bdc.2012.1624","volume":"99","author":"D Psimaras","year":"2012","unstructured":"Psimaras, D. et al. Complications neurologiques centrales des chimioth\u00e9rapies cytotoxiques et des th\u00e9rapies cibl\u00e9es [Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies]. Bull Cancer. 99(9), 851\u2013863 (2012).","journal-title":"Bull Cancer."},{"issue":"6","key":"94477_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41409-022-01648-z","volume":"57","author":"L Schenone","year":"2022","unstructured":"Schenone, L. et al. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Bone Marrow Transplant. 57(6), 966\u2013974 (2022).","journal-title":"Bone Marrow Transplant."},{"key":"94477_CR12","unstructured":"Aboubakr O, et al. Epileptic seizures in patients with primary central nervous system lymphoma: A systematic review. Rev. Neurol. (2023)."},{"issue":"2","key":"94477_CR13","first-page":"105","volume":"9","author":"PB van der Meer","year":"2021","unstructured":"van der Meer, P. B. et al. Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members [published correction appears in Neurooncol Pract. 2022 Oct 19;10(1):106. 10.1093\/nop\/npac082]. Neurooncol. Pract. 9(2), 105\u2013113 (2021) (Published 2021 Oct 2).","journal-title":"Neurooncol. Pract."},{"issue":"1","key":"94477_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11060-019-03362-1","volume":"146","author":"BE Youngerman","year":"2020","unstructured":"Youngerman, B. E. et al. Patterns of seizure prophylaxis after oncologic neurosurgery. J. Neurooncol. 146(1), 171\u2013180 (2020).","journal-title":"J. Neurooncol."},{"issue":"9","key":"94477_CR15","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1200\/JCO.22.00826","volume":"41","author":"JA Mutter","year":"2023","unstructured":"Mutter, J. A. et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas. J. Clin. Oncol. 41(9), 1684\u20131694 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"94477_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12017-020-08624-0","volume":"23","author":"TP Easwaran","year":"2021","unstructured":"Easwaran, T. P. et al. Molecular classification of gliomas is associated with seizure control: a retrospective analysis. Neuromolecular Med. 23(2), 315\u2013326 (2021).","journal-title":"Neuromolecular Med."},{"issue":"19","key":"94477_CR17","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","volume":"88","author":"H Chen","year":"2017","unstructured":"Chen, H. et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 88(19), 1805\u20131813 (2017).","journal-title":"Neurology."},{"issue":"9","key":"94477_CR18","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s12031-021-01837-3","volume":"71","author":"H Xing","year":"2021","unstructured":"Xing, H., Song, Y., Zhang, Z. & Koch, P. D. Clinical characteristics of BRAF V600E gene mutation in patients of epilepsy-associated brain tumor: A meta-analysis. J. Mol. Neurosci. 71(9), 1815\u20131824 (2021).","journal-title":"J. Mol. Neurosci."},{"issue":"9","key":"94477_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/neuonc\/noac003","volume":"24","author":"A Mortazavi","year":"2022","unstructured":"Mortazavi, A. et al. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro Oncol. 24(9), 1423\u20131435 (2022).","journal-title":"Neuro Oncol."},{"issue":"2","key":"94477_CR20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","volume":"34","author":"I Hern\u00e1ndez-Verdin","year":"2023","unstructured":"Hern\u00e1ndez-Verdin, I. et al. Molecular and clinical diversity in primary central nervous system lymphoma. Ann. Oncol. 34(2), 186\u2013199 (2023).","journal-title":"Ann. Oncol."},{"issue":"4","key":"94477_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/epi.13671","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher, R. S. et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 58(4), 531\u2013542 (2017).","journal-title":"Epilepsia."},{"issue":"10","key":"94477_CR22","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier, C. et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 94(10), e1027\u2013e1039 (2020).","journal-title":"Neurology."},{"issue":"4","key":"94477_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/ijmpo.ijmpo_202_16","volume":"38","author":"CK Puligundla","year":"2017","unstructured":"Puligundla, C. K. et al. Clinicopathological features and outcomes in primary central nervous system lymphoma: a 10-year experience. Indian J. Med. Paediatr. Oncol. 38(4), 478\u2013482 (2017).","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"5","key":"94477_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209748","volume":"103","author":"O Aboubakr","year":"2024","unstructured":"Aboubakr, O. et al. Epilepsy in patients with primary CNS lymphoma: Prevalence, risk factors, and prognostic significance. Neurology. 103(5), e209748 (2024).","journal-title":"Neurology."},{"key":"94477_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jns.2019.03.011","volume":"400","author":"J Fox","year":"2019","unstructured":"Fox, J. et al. Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features. J. Neurol. Sci. 400, 34\u201338 (2019).","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"94477_CR26","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00415-021-10396-x","volume":"268","author":"M Decav\u00e8le","year":"2021","unstructured":"Decav\u00e8le, M. et al. Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. J. Neurol. 268(6), 2141\u20132150 (2021).","journal-title":"J. Neurol."},{"issue":"9","key":"94477_CR27","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/neuonc\/now033","volume":"18","author":"S Langner-Lemercier","year":"2016","unstructured":"Langner-Lemercier, S. et al. Primary CNS lymphoma at first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 18(9), 1297\u20131303 (2016).","journal-title":"Neuro Oncol."},{"issue":"2","key":"94477_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11060-010-0252-3","volume":"101","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar, S., Bayraktar, U. D., Ramos, J. C., Stefanovic, A. & Lossos, I. S. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J. Neurooncol. 101(2), 257\u2013265 (2011).","journal-title":"J. Neurooncol."},{"issue":"1","key":"94477_CR29","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1038\/s41467-024-48746-8","volume":"15","author":"P Bourdillon","year":"2024","unstructured":"Bourdillon, P. et al. Differential cortical layer engagement during seizure initiation and spread in humans. Nat. Commun. 15(1), 5153 (2024).","journal-title":"Nat. Commun."},{"issue":"6","key":"94477_CR30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.clinph.2012.11.015","volume":"124","author":"F Chassoux","year":"2013","unstructured":"Chassoux, F. et al. Dysembryoplastic neuroepithelial tumors: epileptogenicity related to histologic subtypes. Clin. Neurophysiol. 124(6), 1068\u20131078 (2013).","journal-title":"Clin. Neurophysiol."},{"issue":"1\u20132","key":"94477_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.eplepsyres.2011.07.004","volume":"97","author":"C Barba","year":"2011","unstructured":"Barba, C. et al. Intrinsic epileptogenicity of gangliogliomas may be independent from co-occurring focal cortical dysplasia. Epilepsy Res. 97(1\u20132), 208\u2013213 (2011).","journal-title":"Epilepsy Res."},{"issue":"4","key":"94477_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/(SICI)1097-4547(19980815)53:4<502::AID-JNR13>3.0.CO;2-3","volume":"53","author":"JD Feldman","year":"1998","unstructured":"Feldman, J. D. et al. Seizure activity induces PIM-1 expression in brain. J. Neurosci. Res. 53(4), 502\u2013509 (1998).","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"94477_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-022-04076-7","volume":"160","author":"MG Xie","year":"2022","unstructured":"Xie, M. G. et al. The cognitive functions and seizure outcomes of patients with low-grade epilepsy-associated neuroepithelial tumors. J Neurooncol. 160(1), 1\u201312 (2022).","journal-title":"J Neurooncol."},{"issue":"7","key":"94477_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s11912-023-01410-8","volume":"25","author":"NS Hauff","year":"2023","unstructured":"Hauff, N. S. & Storstein, A. Seizure management and prophylaxis considerations in patients with brain tumors. Curr. Oncol. Rep. 25(7), 787\u2013792 (2023).","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"94477_CR35","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","volume":"23","author":"T Walbert","year":"2021","unstructured":"Walbert, T. et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 23(11), 1835\u20131844 (2021).","journal-title":"Neuro Oncol."},{"issue":"7","key":"94477_CR36","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","volume":"34","author":"C Happold","year":"2016","unstructured":"Happold, C. et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J. Clin Oncol. 34(7), 731\u2013739 (2016).","journal-title":"J. Clin Oncol."},{"issue":"3","key":"94477_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11060-016-2191-0","volume":"129","author":"KM Knudsen-Baas","year":"2016","unstructured":"Knudsen-Baas, K. M., Engeland, A., Gilhus, N. E., Storstein, A. M. & Owe, J. F. Does the choice of antiepileptic drug affect survival in glioblastoma patients?. J. Neurooncol. 129(3), 461\u2013469 (2016).","journal-title":"J. Neurooncol."},{"issue":"6","key":"94477_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/CCO.0000000000000876","volume":"34","author":"PB van der Meer","year":"2022","unstructured":"van der Meer, P. B. et al. Management of epilepsy in brain tumor patients. Curr. Opin. Oncol. 34(6), 685\u2013690 (2022).","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"94477_CR39","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/epi.17508","volume":"64","author":"S Fairclough","year":"2023","unstructured":"Fairclough, S., Goodden, J., Chumas, P., Mathew, R. & Maguire, M. Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure. Epilepsia. 64(4), 857\u2013865 (2023).","journal-title":"Epilepsia."},{"issue":"1","key":"94477_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/noad154","volume":"26","author":"EK Avila","year":"2024","unstructured":"Avila, E. K. et al. Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. Neuro Oncol. 26(1), 7\u201324 (2024).","journal-title":"Neuro Oncol."},{"issue":"1","key":"94477_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12957-022-02772-2","volume":"20","author":"H Ge","year":"2022","unstructured":"Ge, H. et al. Does epilepsy always indicate worse outcomes? A longitudinal follow-up analysis of 485 glioma patients. World J. Surg. Oncol. 20(1), 297 (2022) (Published 2022 Sep 19).","journal-title":"World J. Surg. Oncol."},{"issue":"10399","key":"94477_CR42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(23)01048-6","volume":"402","author":"AA Asadi-Pooya","year":"2023","unstructured":"Asadi-Pooya, A. A., Brigo, F., Lattanzi, S. & Blumcke, I. Adult epilepsy. Lancet. 402(10399), 412\u2013424 (2023).","journal-title":"Lancet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94477-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94477-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94477-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:44:20Z","timestamp":1742960660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94477-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94477"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94477-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10017"}}